Literature DB >> 27722895

High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection.

Zhenhai Lu1,2,3, Jianhong Peng1,2,3, Zhiqiang Wang4,2,3, Zhizhong Pan1,2,3, Yunfei Yuan5,2,3, Desen Wan1,2,3, Binkui Li6,7,8.   

Abstract

Oligometastasis is defined as a transitional state between localized and widespread systemic metastatic cancers. In colorectal cancer, the prognostic factors and prognostic value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for patients with colorectal liver oligometastases (CLOM) undergoing hepatic resection have not been well explored. Therefore, the present study included 141 patients with CLOM (≤5 liver metastases) who underwent R0 resection from 2005 to 2012. The association of clinicopathological factors including preoperative CA19-9 and CEA levels with overall survival (OS) was analyzed with univariate and multivariate analyses. Kaplan-Meier analysis showed that patients with high CA19-9 levels tended to have poorer OS than those with low levels (median OS 21.5 vs. 64.0 months, P = 0.002). Preoperative CEA levels were not significantly associated with OS (P > 0.05). Univariate and multivariate analyses demonstrated that larger tumor size of liver metastases (HR 1.911; 95 % CI 1.172-3.114; P = 0.009), bilobar distribution (HR 1.776; 95 % CI 1.097-2.873; P = 0.019), and higher preoperative CA19-9 levels (HR 1.954; 95 % CI 1.177-3.242; P = 0.010) were independent predictors of poor OS for patients with CLOM. Our study identified tumor size, distribution, and preoperative CA19-9 levels as independent prognostic factors for OS of patients with CLOM. In particular, measurement of preoperative CA19-9 levels offers an easy tool that could help identify high-risk patients and aid in improving the management of patients with CLOM.

Entities:  

Keywords:  CA19-9; Colon cancer; Hepatectomy; Oligometastasis; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27722895     DOI: 10.1007/s12032-016-0838-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  34 in total

1.  Ca 19-9 in the monitoring of colorectal cancer after surgery.

Authors:  F Franchi; C Pastore; P Izzo; E Calió
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

2.  The Prognostic Value of Preoperative Serum CEA and CA19-9 Values in Stage I-III Colorectal Cancer.

Authors:  Ren-fie Wang; Bao-Rong Song; Jun-Jie Peng; Guo-Xiang Cai; Fang-Qi Liu; Ming-He Wang; San-Jun Cai; Xu Ye
Journal:  Hepatogastroenterology       Date:  2014-06

3.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

4.  Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases.

Authors:  Raphael L C Araujo; Mithat Gönen; Peter Allen; Ronald DeMatteo; Peter Kingham; William Jarnagin; Michael D'Angelica; Yuman Fong
Journal:  Ann Surg Oncol       Date:  2015-01-13       Impact factor: 5.344

Review 5.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

Review 6.  Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis.

Authors:  Fausto Petrelli; Andrea Coinu; Alberto Zaniboni; Filippo Pietrantonio; Sandro Barni
Journal:  Rev Recent Clin Trials       Date:  2016

7.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Tumor markers in staging and prognosis of colorectal carcinoma.

Authors:  M Levy; V Visokai; L Lipska; O Topolcan
Journal:  Neoplasma       Date:  2008       Impact factor: 2.575

9.  Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.

Authors:  Ryo Takagawa; Syoichi Fujii; Mitsuyoshi Ohta; Yasuhiko Nagano; Chikara Kunisaki; Shigeru Yamagishi; Shunichi Osada; Yasushi Ichikawa; Hiroshi Shimada
Journal:  Ann Surg Oncol       Date:  2008-10-10       Impact factor: 5.344

10.  Liver resection for colorectal cancer metastases.

Authors:  S Gallinger; J J Biagi; G G Fletcher; C Nhan; L Ruo; R S McLeod
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

View more
  16 in total

1.  Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy.

Authors:  Jia-Ming Liu; Yan-Yan Wang; Wei Liu; Da Xu; Kun Wang; Bao-Cai Xing
Journal:  Int J Colorectal Dis       Date:  2021-01-09       Impact factor: 2.571

2.  Identification of the Minimum Combination of Serum microRNAs to Predict the Recurrence of Colorectal Cancer Cases.

Authors:  Yukihiro Yoshikawa; Mitsuko Fukunaga; Junichi Takahashi; Dai Shimizu; Takaaki Masuda; Tsunekazu Mizushima; Kazutaka Yamada; Masaki Mori; Hidetoshi Eguchi; Yuichiro Doki; Takahiro Ochiya; Koshi Mimori
Journal:  Ann Surg Oncol       Date:  2022-09-29       Impact factor: 4.339

3.  Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.

Authors:  Yijiao Chen; Wenju Chang; Li Ren; Jingwen Chen; Wentao Tang; Tianyu Liu; Mi Jian; Yu Liu; Ye Wei; Jianmin Xu
Journal:  Oncologist       Date:  2020-03-17

4.  High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer.

Authors:  Eiji Hidaka; Chiyo Maeda; Kenta Nakahara; Kunihiko Wakamura; Yasuhiro Ishiyama; Shoji Shimada; Junichi Seki; Yojiro Takano; Sonoko Oae; Yuta Enami; Naruhiko Sawada; Fumio Ishida; Shin-Ei Kudo
Journal:  Gastrointest Tumors       Date:  2019-01-24

5.  Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis.

Authors:  Junzhong Lin; Jianhong Peng; Yixin Zhao; Baojia Luo; Yujie Zhao; Yuxiang Deng; Qiaoqi Sui; Yuanhong Gao; Zhifan Zeng; Zhenhai Lu; Zhizhong Pan
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-11       Impact factor: 4.553

6.  Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival.

Authors:  Jianhong Peng; Hui Li; Qingjian Ou; Junzhong Lin; Xiaojun Wu; Zhenhai Lu; Yunfei Yuan; Desen Wan; Yujing Fang; Zhizhong Pan
Journal:  Onco Targets Ther       Date:  2017-07-27       Impact factor: 4.147

7.  Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Authors:  Zhizhong Pan; Jianhong Peng; Junzhong Lin; Gong Chen; Xiaojun Wu; Zhenhai Lu; Yuxiang Deng; Yujie Zhao; Qiaoqi Sui; Desen Wan
Journal:  Cancer Commun (Lond)       Date:  2018-05-29

8.  Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis.

Authors:  Hui Chang; Xin Yu; Kai Chen; Qiao-Xuan Wang; Shu Zhang; Zhi-Fan Zeng; Pei-Rong Ding; Zhi-Zhong Pan; Wei-Wei Xiao; Yuan-Hong Gao
Journal:  J Cancer       Date:  2018-10-21       Impact factor: 4.207

9.  Serum CNPY2 isoform 2 represents a novel biomarker for early detection of colorectal cancer.

Authors:  Jianhong Peng; Qingjian Ou; Zhizhong Pan; Rongxin Zhang; Yujie Zhao; Yuxiang Deng; Zhenhai Lu; Lin Zhang; Caixia Li; Yaxian Zhou; Jian Guo; Desen Wan; Yujing Fang
Journal:  Aging (Albany NY)       Date:  2018-08-02       Impact factor: 5.682

10.  Is long interval from neoadjuvant chemoradiotherapy to surgery optimal for rectal cancer in the era of intensity-modulated radiotherapy?: a prospective observational study.

Authors:  Hui Chang; Wu Jiang; Wei-Jun Ye; Ya-Lan Tao; Qiao-Xuan Wang; Wei-Wei Xiao; Yuan-Hong Gao
Journal:  Onco Targets Ther       Date:  2018-09-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.